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IMPORTANCE There is a paucity of controlled treatment trials for the treatment of conversion
disorder, seizures type, also known as psychogenic nonepileptic seizures (PNES).
Psychogenic nonepileptic seizures, the most common conversion disorder, are as disabling as
epilepsy and are not adequately addressed or treated bymental health clinicians.
OBJECTIVE To evaluate different PNES treatments compared with standardmedical care
(treatment as usual).
DESIGN, SETTING, AND PARTICIPANTS Pilot randomized clinical trial at 3 academicmedical
centers with mental health clinicians trained to administer psychotherapy or
psychopharmacology to outpatients with PNES. Thirty-eight participants were randomized in
a blocked schedule among 3 sites to 1 of 4 treatment arms and were followed up for 16 weeks
between September 2008 and February 2012; 34 were included in the analysis.
INTERVENTIONS Medication (flexible-dose sertraline hydrochloride) only, cognitive
behavioral therapy informed psychotherapy (CBT-ip) only, CBT-ip with medication
(sertraline), or treatment as usual.
MAIN OUTCOMES ANDMEASURES Seizure frequencywas the primary outcome; psychosocial
and functioningmeasures, including psychiatric symptoms, social interactions, quality of life,
and global functioning, were secondary outcomes. Data were collected prospectively, weekly,
and with baseline, week 2, midpoint (week 8), and exit (week 16) batteries. Within-group
analyses for each armwere performed on primary (seizure frequency) and secondary
outcomes from treatment-blinded raters using an intention-to-treat analysis.
RESULTS The psychotherapy (CBT-ip) arm showed a 51.4% seizure reduction (P = .01) and
significant improvement from baseline in secondary measures including depression, anxiety,
quality of life, and global functioning (P < .001). The combined arm (CBT-ip with sertraline)
showed 59.3% seizure reduction (P = .008) and significant improvements in some secondary
measures, including global functioning (P = .007). The sertraline-only arm did not show a
reduction in seizures (P = .08). The treatment as usual group showed no significant seizure
reduction or improvement in secondary outcomemeasures (P = .19).
CONCLUSIONS AND RELEVANCE This pilot randomized clinical trial for PNES revealed
significant seizure reduction and improved comorbid symptoms and global functioning with
CBT-ip for PNES without and with sertraline. There were no improvements in the
sertraline-only or treatment-as-usual arms. This study supports the use of manualized
psychotherapy for PNES and successful training of mental health clinicians in the treatment.
Future studies could assess larger-scale intervention dissemination.
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P sychogenic nonepileptic seizures (PNES) are a somato-form conversion disorder manifesting as paroxysmalevents not associated with electroencephalographic
(EEG) epileptiform correlates, and they have psychological
underpinnings.1Theyarenot responsive to treatmentwith,and
maybeworsenedby, antiepileptic drugs.2,3 Theyoccurworld-
wide, and in theUnited States up to 20%of civilians andup to
25% of veterans diagnosed as having epilepsy actually have
PNES,4makingPNESas commonasmultiple sclerosis andPar-
kinson disease5 and as disabling as epilepsy.6 The phenom-
enologyandpsychological underpinningsofPNESarewell de-
lineated, including an understanding of risk factors and
prognostic features.7 Much less is known, however, about ef-
fective treatments for PNES, resulting in many patients re-
turning to neurology offices and emergency departments be-
causeof recurrent seizures. Surveysadministered toAmerican
Epilepsy Society members and UK clinicians described stan-
dardmedical care (treatmentasusual [TAU]) forPNESasaneu-
rologist sharing the diagnosis with the patient and family, if
present,while continuing to followupwith thepatient, taper-
ing the antiepileptic drug in lone PNES, and the majority not
initiatingpsychotropic treatmentbutmakinga referral toapsy-
chiatrist or psychologist.8,9 Many times after diagnosis, pa-
tients with PNES do not pursuemental health care follow-up
or they receive only supportive psychotherapy, which is not
effective for PNES10 or for depression.11,12
Prior pilot treatment trials revealed that sertraline hydro-
chloride or cognitive behavioral therapy (CBT) may be effec-
tive in reducing PNES. Patients receiving sertraline reported
a 45% reduction in PNES, compared with an 8% increase in
PNES in the placebo group.13 An open-label psychotherapy
study for PNES10 used an epilepsy therapyworkbook14modi-
fied to target dysfunctional cognitions and behaviors in pa-
tients with PNES.15 Eleven of 17 individual therapy interven-
tion completers (65%) reported no seizures by the end of the
12-week trial. The 12-session, therapist-guided seizure treat-
mentworkbook focusedongaining control of seizures and in-
cluded training in healthy communication, understanding
medications, conducting functional behavioral analysis, and
examining internal and external triggers. In addition to sei-
zure reduction,mean scores on scalesmeasuring depression,
anxiety, somatic symptoms, quality of life (QOL), andpsycho-
social functioning showed improvement frombaseline to the
final session, suggesting that the intervention also improved
psychiatric symptoms, QOL, and functioning.
DespitePNES(formerly referredtoaspseudoseizuresorhys-
teroepilepsy) being recognized for centuries,16 a fully pow-
ered phase 3 intervention randomized clinical trial (RCT) has
not yet been conducted. Although the National Institutes of
HealthEpilepsyBenchmarks identifieddeveloping evidence-
based treatment forPNESasapriority,17nostandards for agen-
eralizable, effective,widespread treatment for PNESare avail-
able.Thus,wehaveconductedapilotRCTdesignedtoevaluate
various treatments for PNES. The secondary aimsof the study
included evaluating the impact of treatment on psychiatric
symptoms,QOL, coping, and general and relational function-
ing and assessing the ability to disseminate the treatment to
other sites.
Methods
The study was approved by the organizing site, Rhode Island
Hospital, andby theStanfordUniversity andUniversityofCin-
cinnati institutional reviewboards.All enrolleesprovidedwrit-
ten informed consent.
Participants aged 18 to 65 years with a video EEG–
confirmed diagnosis of lone PNES and at least 1 event in the
monthpriorwere recruitedbetweenSeptember 2008andFeb-
ruary 2012 (Figure 1). Criteria for the diagnosis of events con-
sisted of stereotypic motor manifestations with or without
change in level of consciousness.18 Exclusion criteria in-
cluded the following: concurrentmixed epilepsy andPNESor
equivocal videoEEG findings in discerning between epileptic
seizures and PNES; use of monoamine oxidase inhibitor or
pimozide within 30 days prior to study entry; current use of
sumatriptan succinate or other serotonin 1 receptor agonist;
allergy or sensitivity to sertraline; current enrollment in CBT
for PNES; current or past-year self-mutilation; frank psycho-
sis; current suicidality with intent to harm self; serious ill-
ness; active substanceor alcoholuseordependence that could
interferewithparticipation;pending litigation; andcurrentap-
plication for long-term disability.
Study Design
Participantswere randomized 1:1:1:1 into 1of4 treatment arms
using a computer-generated blocked randomization. Enroll-
ment was at Rhode Island Hospital initially (n = 28) and con-
tinued in 2010 when 2 other sites were added (Stanford Uni-
versity, n = 7; University of Cincinnati, n = 3), as designed in
thedissemination infrastructuregrant. Patientswere random-
ized to psychotherapy for seizures (CBT informed psycho-
therapy [CBT-ip]; n = 9), flexible-dose sertraline (n = 9), com-
binedCBT-ip andsertraline (n = 10), orTAU (n = 10). Sertraline
was chosenbecause of its limiteddrug-drug interactionswith
antiepileptic drugs and because of its US Food and Drug Ad-
ministration indications for the many diagnostic comorbidi-
ties occurring with PNES (eg, depression, anxiety, posttrau-
matic stress disorder).
A complete history and medical, psychiatric, and neuro-
logical examinations were obtained before or at enrollment.
Clinician-rated assessments and self-report questionnaires
measuringpsychiatric symptoms, social interactions,QOL,and
global functioning were given at baseline, treatment initia-
tion (week 2), midpoint (week 8), and exit (week 16). As is the
case in all seizure trials andbecause seizures are the source of
disability, seizure frequency was selected as the primary
outcome.19 Seizure frequencywasassesseddailyusingweekly
seizure calendars, with family assisting participants in log-
ging seizure frequency, triggers, andmedical care utilization.
Sertralinehydrochloridewas startedonday 14 and titratedup
to 200 mg or as tolerated. The psychotherapy was adminis-
tered in12weekly, 1-hour, individual sessionsby1 trainedthera-
pist per site starting on day 14 using the modified workbook
from the previous open-label study.10 Uniformity of treat-
ment between sites was assured with pretreatment training;
all therapists underwent one-on-one training with the prin-
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cipal investigator (W.C.L.) on the CBT-ip intervention and
treated 2 patients with PNES prior to the trial, with all ses-
sions filmed forweekly feedbackprovidedby theprincipal in-
vestigator. Participants in theTAUarm followedupwith their
treating neurologist andwere seen biweekly for assessments,
in the same manner as those in the other treatment arms.
Throughout the study, therapy sessions fromall siteswere re-
viewed for treatment fidelity. Treatment providers demon-
strated adherence and competence using a modified Cogni-
tive Therapy Scale20 and a Psychotherapy Rating Scale21 used
in theprior trial10 beforedelivering treatmentandduring treat-
ment across sites.VideoEEGdiagnosis between the3 siteswas
independently validated, with excellent interrater reliability
(κ = 1.00). Participants also provided comments and feed-
back in exit interviews, which were assessed using qualita-
tive methods.
Self-report assessments included theBeckDepression In-
ventory–II, Beck Anxiety Inventory, Barratt Impulsiveness
Scale,DavidsonTraumaScale,DissociativeExperiencesScale,
Side Effects Profile, Symptom Checklist 90, Quality of Life in
Epilepsy Inventory 31, QOL Burden to Family Scale, Expecta-
tions Scale, and Ways of Coping Questionnaire. Clinician-
rated assessments included the Global Assessment of Func-
tioning, Hamilton Depression Rating Scale, Oxford Handicap
Scale, Clinical Global Impressions–Improvement, Clinical
Global Impressions–Severity, and Longitudinal Interval Fol-
low-upEvaluation–Rangeof ImpairedFunctioningTool (aqual-
ity-of-relationshipsmeasure). Treatment-blinded trained rat-
ers assessed clinician-scored outcomes after reliability was
established. Interrater reliabilitywasestablishedbyhaving rat-
ers score a sample of the samepatients andhaving the results
reviewed. Given the nature of interventions delivery, clini-
cians in the study were not blinded to the intervention.
Statistical Analysis
Generalizedlinearmixedmodels fornegativebinomialandPois-
sondatawereused tomodel seizurecountsandemergencyde-
partment visits, respectively, as a function of treatment condi-
tion and time (PROC GLIMMIX; SAS version 9.3 statistical
software; SAS Institute, Inc). Classic sandwich estimationwas
usedtoadjustforanymodelmisspecification.Thisanalysistech-
nique was chosen because of its versatility in modeling indi-
vidual trajectories of count data over time.
Linear trendswere used to test significance of trajectories
on secondary measures across the 4 ordinal assessment peri-
ods using PROCGLIMMIX. The linear trends across these ordi-
nalassessmentswerecomparedbetweengroupsusingorthogo-
nal linearcontrasts.Forclinicalrelevance,differencemeans,95%
confidence intervals, and effect sizes are also presented.
Multiple comparisonswereexaminedwithorthogonal lin-
ear contrastswithαmaintainedat .05using theHolmmethod.
Becausemixedmodeling calculates individual trajectories for
eachparticipant and final seizure countswereunavailable for
only 2 patients, this provided the intention-to-treat approach
Figure 1. CONSORT FlowDiagram of theMultisite Pilot Randomized Clinical Trial for Psychogenic Nonepileptic
Seizures, Comparing Sertraline and/or Cognitive Behavioral Therapy Informed Psychotherapy (CBT-ip)
With Treatment as Usual
589 Assessed for eligibility
551 Excluded
508 Not meeting inclusion criteria
43 Declined to participate
3 Dropped out day after
enrollment and received
no treatment
27 Received allocated intervention
1 Did not receive allocated intervention (CBT-ip)
1 Withdrew (CBT-ip)
7 Received allocated intervention
3 Did not receive allocated intervention
3 Withdrew
1 Lost to follow-up (could not be reached)
1 Discontinued intervention (exited for other
treatment)
2 Lost to follow-up (could not be reached)
3 Discontinued intervention (wanted to start
other treatment)
27 Analyzed
1 Excluded from intention-to-treat analysis
(did not complete baseline after signing
consent)
7 Analyzed
3 Excluded from intention-to-treat analysis
(did not complete baseline after signing
consent)
28 Allocated to interventions
9 Sertraline hydrochloride, 25-200 mg/d
9 CBT-ip
10 CBT-ip and sertraline
10 Allocated to control (standard medical care/
treatment as usual)
38 Randomized
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in theanalyses.As a conservativeeffort, only 2-tailed tests and
confidence intervals were calculated.
Results
A total of 81 patientsmet all inclusion andnoexclusion criteria
andwereeligible fromall 3 sites.Of the81 eligibleparticipants,
38 (46.9%)providedwritten informedconsent for thestudyand
43 (53%) refused toparticipate (similar to ratesofprior trials10).
Three patients dropped out the day after signing consent, 31
completedall sessionsandsurveys,and34were included in the
mixedmodelinganalysis toaccount foran intention-to-treatap-
proach (Figure 1).Thegreatest reasons for screening failures in-
cluded individualsnotbeingeligiblebecauseof current comor-
bid epilepsy (n = 179 [35.2%]), lack of access (n = 111 [21.8%]),
lackof seizure in themonthprior toassessment (n = 29 [5.7%]),
andnothavingavideoEEG–confirmeddiagnosis (n = 26[5.1%]).
Demographic characteristics, clinical factors, andclinical diag-
noses are described in Table 1. There were no between–
Table 1. PatientMedical History Obtained by Interview and Record Reviewa
Characteristic
CBT-ip
(n = 9)
CBT-ip With
Sertraline
(n = 9)
Sertraline
(n = 9)
TAU
(n = 7)
Sociodemographic, self-reported
Age, mean (SD), y 37.9 (11.5) 39.1 (13.2) 39.7 (11.7) 41.6 (8.3)
Age at NES onset, mean (SD), y 33.6 (10.7) 36.7 (13.9) 33.2 (11.9) 39.1 (7.7)
Female, No. (%) 7 (77.8) 9 (100.0) 8 (88.9) 7 (100.0)
Education, mean (SD), y 15.4 (3.9) 15.7 (2.4) 13.0 (1.9) 16.0 (3.6)
Currently employed, No. (%) 2 (22.2) 6 (66.7) 2 (22.2) 2 (28.6)
Currently receiving disability, No. (%) 3 (33.3) 3 (33.3) 4 (44.4) 5 (71.4)
Currently married, No. (%) 4 (44.4) 6 (66.7) 4 (44.4) 2 (28.6)
Currently driving, No. (%) 3 (33.3) 0 3 (33.3) 3 (42.9)
Clinical diagnosis, made by neuropsychiatric
examination and SCID, No. (%)b
Mood disordersc 3 (33.3) 7 (77.8) 9 (100.0) 4 (57.1)
Anxiety disordersd 6 (85.7) 7 (87.5) 7 (100.0) 7 (100.0)
Somatoform disorders other than NES 1 (12.5) 3 (37.5) 2 (28.6) 3 (42.9)
Impulsivity, cluster B 1 (11.1) 1 (11.1) 3 (33.3) 2 (28.6)
Obsessive-compulsive personality disorder,
cluster C
0 2 (22.2) 2 (22.2) 4 (57.1)
Clinical factors, from history at baseline
History of trauma or abuse, No. (%) 7 (77.8) 6 (66.7) 7 (77.8) 6 (85.7)
Previous psychotherapy, No. (%) 6 (66.7) 6 (66.7) 5 (55.6) 3 (42.9)
Treated with psychotropic medications, past
and current, No. (%)
8 (88.9) 8 (88.9) 9 (100.0) 5 (71.4)
Benzodiazepines, No. (%) 6 (66.7) 5 (55.6) 6 (66.7) 2 (28.6)
Antidepressants, No. (%) 4 (44.4) 7 (77.8) 6 (66.7) 5 (71.4)
Antipsychotics, No. (%) 2 (22.2) 1 (11.1) 0 2 (28.6)
On AEDs at baseline, No. (%) 5 (55.6) 5 (55.6) 7 (77.8) 3 (42.9)
Total lifetime AEDs, mean (SD), No. 2.67 (1.2) 4.00 (3.4) 3.11 (1.9) 4.00 (1.6)
Time from NES onset to NES diagnosis, y
Mean (SD) 3.7 (4.6) 1.4 (1.3) 5.6 (5.6) 2.2 (3.4)
Median (range) 1.0 (0.0-10.6) 1.6 (0.0-3.7) 3.1 (0.2-14.4) 0.5 (0.1-9.5)
Time from NES diagnosis to NES
treatment, y
Mean (SD) 0.4 (0.7) 1.5 (2.6) 1.4 (2.2) 0.6 (1.2)
Median (range) 0.2 (0.0-2.1) 0.3 (0.0-7.0) 0.5 (0.1-6.9) 0.2 (0.04-3.4)
Abnormal neurological examination findings
at enrollment, No. (%)
7 (87.5) 5 (55.6) 7 (87.5) 7 (100.0)
Abnormal brain MRI findings, past or at
enrollment, No. (%)
3 (60.0) 4 (50.0) 4 (57.1) 3 (50.0)
30-min EEG tracing or video EEG findings,
No. (%)
Interictal epileptiform activity 0 0 1 (14.2) 0
Slowing, only EEG abnormality 0 2 (28.6) 1 (14.2) 0
Biological family history of seizures 2 (22.2) 3 (33.3) 2 (22.2) 3 (42.9)
History of head injury 3 (37.5) 5 (55.6) 6 (66.7) 7 (100.0)
Abbreviations: AEDs, antiepileptic
drugs; CBT-ip, cognitive behavioral
therapy informed psychotherapy;
EEG, electroencephalography;
MRI, magnetic resonance imaging;
NES, nonepileptic seizures;
SCID, Structured Clinical Interview
for DSM-IVDisorders; TAU, treatment
as usual.
a There were no significant
differences between treatment
groups in demographic and
descriptive variables collected at
enrollment.
bNot mutually exclusive.
c Seven patients have 2 different
mood disorders.
d Four patients have 5 different
anxiety disorders, 5 patients have
4 different anxiety disorders,
3 patients have 3 different anxiety
disorders, 10 patients have
2 different anxiety disorders, and
6 patients have 1 anxiety disorder.
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treatment group significant differences in demographic vari-
ables at enrollment. Sample sizes did not allow for between-
site analysis.
Primary Analysis of Treatment Effect on Seizure Frequency
Within-treatment condition analyses indicate significant re-
ductions in the number of monthly seizures reported by pa-
tients in the CBT-ip condition and the CBT-ip with sertraline
condition relative to prospective baseline. Specifically, pa-
tients in the CBT-ip condition reported 51.4% fewer total
monthly seizures (P = .01) andpatients in theCBT-ipwith ser-
traline condition reported 59.3% fewer total monthly sei-
zures (P = .008). Patients in the sertraline condition experi-
enced 26.5% fewer total monthly seizures; however, this was
not statistically significant (P = .08). Patients in the TAU con-
dition did not experience a significant change in the total
monthly number of seizures (P = .19). Thepilot studywasnot
powered to detect between-group differences and was de-
signed for within-group analyses. A main effect was ob-
served for time when modeling total seizures (F1,30 = 17.44;
P < .001). No interaction effect or between–treatment condi-
tionseizure trajectorieswereobserved.These findingsaresum-
marized in Table 2 and Figure 2.
Themajority of patients in the 3 treatment conditions re-
ported a 50% or greater reduction in the number of seizures
from enrollment to exit (CBT-ip, 55.6%; CBT-ip with sertra-
line, 66.7%; sertraline, 55.6%). No change in seizures oc-
curred in theCBT-ip (n = 1), CBT-ipwith sertraline (n = 1), ser-
traline (n = 1), and TAU (n = 2) groups, and seizure increases
were reported in the CBT-ip (n = 0), CBT-ip with sertraline
(n = 1), sertraline (n = 4), and TAU (n = 2) groups. Several pa-
tients also reported seizure freedom (0 seizures) at the exit in-
terview (CBT-ip, n = 3; CBT-ip with sertraline, n = 5; sertra-
line, n = 1; andTAU, n = 1 [excluding thosewithno seizures in
the prospective baseline period]). When comparing patients
whoreceivedCBT-ipwith thosewhodidnotbycombiningcon-
ditions, the odds of achieving seizure freedomwas 6.2 times
greater for those receiving CBT-ip relative to those not receiv-
ing CBT-ip (P = .06).
Regarding patient expectations, a model examining sei-
zure counts given treatment arm, time, and level of positive
prognosis expectations (using a 1- to 5-point Likert scale at en-
rollment) did not yield a significant interaction effect. Thus,
it does not appear that the level of self-predicted positive ex-
pectation influenced the effect of time and treatment arm for
seizure count.
Treatment Effect on Secondary Outcomes
Secondary outcomes including depression, anxiety, somatic
symptoms, QOL, impulsivity, and psychosocial functioning
were examinedwithin groups and between treatment condi-
tions. Several between-group time-by-treatment interaction
effects and main effects for time and condition were ob-
served in secondary measures (eTable 1 in the Supplement).
More importantly, results frommultiple comparison tests in-
dicate that when differences existed between treatment con-
Table 2.Within-Treatment ConditionMonthly Seizure Count Change
Treatment Patients, No. Slope (SE) [95% CI] T438 P Value
Posttreatment/Pretreatment Ratio
of Seizures, Mean (SE) [95% CI] Reduction, %
CBT-ipa 9 −0.72 (0.3) [−1.3 to −0.2] −2.95 .01 0.49 (0.1) [0.28 to 0.84] 51.4
CBT-ip with sertralinea 9 −0.90 (0.3) [−1.6 to −0.2] −2.69 .008 0.41 (0.1) [0.21 to 0.79] 59.3
Sertraline 9 −0.31 (0.2) [−0.6 to 0.03] −1.78 .08 0.74 (0.1) [0.52 to 1.03] 26.5
Treatment as usual 7 −0.40 (0.3) [−1.0 to 0.2] −1.32 .19 0.67 (0.2) [0.37 to 1.21] 33.8
Abbreviation: CBT-ip, cognitive behavioral therapy informed psychotherapy. a Statistically significant differences.
Figure 2. Monthly Trajectory of Seizure Counts by Treatment Condition
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ditions, patients in theCBT-ip conditionoften improvedmore
than those in theMED condition, the TAU condition, or both.
The studywas not designed to randomize patients strati-
fied on secondary measures at baseline. Nevertheless, treat-
ment armswere found tobeequivalent across secondarymea-
sures at baseline, with the exceptions of scores on anxiety,
depression, and some somatic symptomscales, including the
Beck Anxiety Inventory (F3,24 = 3.43; P = .03), Beck Depres-
sion Inventory–II (F3,30 = 4.38; P = .01), Hamilton Depression
Rating Scale (F3,24 = 3.25; P = .04), Longitudinal Interval Fol-
low-up Evaluation–Range of Impaired Functioning Tool
(F3,30 = 2.92; P = .05), and Side Effects Profile (F3,30 = 4.38;
P = .01).Multiple comparisons indicate thatparticipants in the
CBT-ipwith sertraline group reported lower scores than those
in theTAUgroup for theBeckAnxiety Inventory,BeckDepres-
sion Inventory–II, and SideEffects Profile; those in theCBT-ip
with sertraline group also reported lower scores on the Beck
DepressionInventory–II thanthose in thesertralinegroup.Mul-
tiple comparisons did not indicate differences between treat-
mentarms for theLongitudinal IntervalFollow-upEvaluation–
Rangeof ImpairedFunctioningTool andHamiltonDepression
Rating Scale. As a conservative effort, the potential moderat-
ing influenceof thesebaselinedifferencesonseizurecountwas
thereforeexamined.However,nosignificant interactionswere
observed, indicating that the baseline differences on second-
arymeasures did not have amoderating influence on seizure
count (Table 3).
Linear trend estimates and standard errors on secondary
outcomeswereexaminedwithineachtreatmentconditionrela-
tive to enrollment spanning 4 assessment periods (ie, base-
line [enrollment], intervention initiation,midpoint, and final
[exit]). Significant improvementswere observedonmost sec-
ondaryoutcomes for patients in theCBT-ip condition and sev-
eral outcomes for patients in the CBT-ip with sertraline con-
dition.Nosignificant improvementswereobservedforpatients
in the sertraline condition. No measures improved in the pa-
tients in the TAU condition. As this is a pilot study, trends to-
ward significancewere also noted. Additionally, baseline and
exit differential effect sizes were calculated for each condi-
tion. These results are summarized in eTable 2 in the Supple-
ment, including categorical changes for the Ways of Coping
Questionnaire. The eFigure in the Supplement includesmean
plots of outcomes for secondarymeasures by treatment con-
dition over the 4 assessment periods.
Qualitative reports from patient exit interviews revealed
common themes found in the therapy groups, including ap-
preciation fornewlyacquiredcoping skills (even if seizuresdid
not abate completely), positiveeffectson relationships andac-
tivities, and medication adverse effects.
Lastly, generalized linearmixedmodels assuming a Pois-
sondistribution comparing thenumber of emergencydepart-
mentvisitsprior toandduringthetrial (standardizedbymonth)
detected a significant time × treatment effect (F3,60 = 4.81;
P = .005). More importantly, Bonferroni multiple compari-
sons indicate that participants in the CBT-ip condition re-
ported significantly fewer visits to the emergency depart-
mentduring the trial relative tobaseline (estimateddifference
[SE], −1.3 [0.2]; t60 = 5.43; P < .001).
Discussion
In this pilotmultisiteRCT, a time-limitedCBT-ip–basedmanu-
alized intervention for PNES administered by trained clini-
Table 3. Between-Treatment Difference on SecondaryMeasures (Linear Trend)a
Treatment Linear Trend Difference (SE) [95% CI] T116 P Value
Global Assessment of Functioning
CBT-ip vs CBT-ip with sertraline 37.5 (20.9) [−18.5 to 93.6] 1.8 .37
CBT-ip vs sertraline 44.4 (25.0) [−22.7 to 111.5] 1.8 .37
CBT-ip vs treatment as usualb 66.8 (23.3) [4.3 to 129.3] 2.9 .03
CBT-ip with sertraline vs sertraline 6.9 (21.4) [−50.6 to 64.4] 0.3 .75
CBT-ip with sertraline vs treatment as usual 29.2 (19.4) [−22.8 to 81.3] 1.5 .40
Sertraline vs treatment as usual 28.1 (23.8) [−35.7 to 91.8] 1.2 .48
Oxford Handicap Scale
CBT-ip vs CBT-ip with sertralineb −4.2 (1.4) [−8.0 to −0.3] −2.9 .02
CBT-ip vs sertralineb −6.1 (1.9) [−11.3 to −0.9] −3.1 .01
CBT-ip vs treatment as usualb −6.3 (1.7) [−10.8 to −1.7] −3.7 .002
CBT-ip with sertraline vs sertraline −1.9 (2.0) [−7.2 to 3.4] −1.0 .69
CBT-ip with sertraline vs treatment as usual −2.1 (1.7) [−6.7 to 2.6] −1.2 .69
Sertraline vs treatment as usual −1.9 (2.2) [−7.7 to 4.0] −0.9 .69
Clinical Global Impressions–Severity
CBT-ip vs CBT-ip with sertraline −2.5 (2.8) [−9.9 to 4.9] −0.9 .69
CBT-ip vs sertraline −5.8 (2.4) [−12.2 to 0.6] −2.4 .09
CBT-ip vs treatment as usualb −7.2 (2.2) [−13.1 to −1.2] −3.3 .01
CBT-ip with sertraline vs sertraline −3.3 (3.0) [−11.4 to 4.9] −1.1 .69
CBT-ip with sertraline vs treatment as usual −4.6 (2.9) [−12.4 to 3.1] −1.6 .44
Sertraline vs treatment as usual −3.1 (2.5) [−9.9 to 3.8] −1.2 .69
Abbreviation: CBT-ip, cognitive
behavioral therapy informed
psychotherapy.
a Holm-Bonferroni method was used
for tests of multiple comparisons.
b Statistically significant.
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cians resulted in significant reduction in PNES and improved
comorbid psychiatric symptoms, QOL, and functioning. The
psychotherapy arm showed significant improvements com-
pared with TAU, which showed no improvements in primary
or secondary outcomes. The secondary goalwas to assess the
feasibility of disseminating the treatment10 to other locations
andmental health clinicians.
Some studies of combined treatments for depression and
anxietyshowedgreaterbenefitofcombinedpsychotherapyand
medication thaneither treatment alone.22,23 The greater over-
all secondaryoutcome improvements in theCBT-ip–only arm,
compared with the CBT-ip with sertraline arm, was unex-
pected. Given the trend in seizure reduction of 26.5% in the
sertraline group (P = .08),wehypothesize that adding a selec-
tive serotonin reuptake inhibitor provides some reduction in
seizures,13 but medication adverse effects in this already so-
matically focused population may have mitigated its impact
on the comorbidities. The selective serotonin reuptake inhibi-
tor effects that may impact a fear-extinction domain24 could
have a differential effect on somatic symptoms. Qualitative
review of patients on medication perspectives revealed
statements such as, “My seizures are better, but I’vehadmore
upset stomach on the medication.” The adverse effect–
constitutional symptoms from the medication may have
contributed to less reduction in the anxiety and depression
scores than in the CBT-ip–only arm.
Inadditiontosignificantseizurereductionwiththetherapy,
comorbiddepression, anxiety,dissociation, andsomatic symp-
toms also improved significantly. Given that comorbidities are
the rule in thePNESpopulation, thestudywasdesigned to take
allcomers; thus,weintentionallydidnotrestrict inclusionbased
on common comorbidities (eg, posttraumatic stress disorder,
anxiety, depression, Axis II traits and disorders, trauma his-
tory, familydysfunction) for external validity.Theconsistency
ofmultiplecomorbiditiesandstressors composes, ineffect, the
homogeneity of PNES. This intervention therefore treats pa-
tients with PNES, with all of their heterogeneities.25
Functioning, coping mechanisms, and QOL also im-
proved. Patients in the CBT-ip (both alone and with sertra-
line) arms used unhealthy coping techniques at enrollment,
and by exit they were using healthy techniques. The CBT in-
formed therapydiffers fromsupportive therapy, addresses tra-
ditional targets ofCBT techniques (thoughts andschema), and
incorporates interpersonal (targeting communication),mind-
fulness (targeting distress tolerance), and dynamic (targeting
developmental) therapy methods that help develop healthy
coping.26 Drawing important techniques from other modali-
ties accounts for its reach beyond solely treating seizures and
differentiates this therapy fromother treatments.27 Although
not powered to do so, the CBT-ip–only arm was significantly
better thanTAU for global functioning,OxfordHandicapScale
scores, andClinicalGlobal Impressions–Severity scores.Given
improvements in the treatment groups contrasted against no
improvements in the TAU group, the differences do not ap-
pear to be an effect of the natural course of the illness when
patientshadreceivedother treatments.28,29That theeffectwas
demonstratedwith a small sample underscores the impact of
the intervention.
Patients with seizures have travel limitations, and some
patients receivingCBT-iphad to reschedule appointments be-
cause of transportation or weather. As was done in the pilot
open-label trial,10 Clinical VideoTelehealthwasused success-
fully again by the Rhode IslandHospital for 2 patients for ses-
sions in thisRCTwhen theyhad travel difficulties, and thisdid
notaffectparticipationoroutcomes.TheVeteransAffairsMedi-
cal Centers use Clinical Video Telehealth30 for veterans with
PNES. Tele–mental health care currently is not reimbursedby
many insurance providers. Given the expense of this disor-
der inpatientswho receive inappropriate treatment,31-34Clini-
calVideoTelehealthhas thepotential to improveaccess tocare
for civilians and shouldbeassessed in a formal trial.Overcom-
ing diagnosis and treatment obstacles (eg, transportation,
providing treatment in remoteareas), therebyaddressing treat-
ment gaps, could greatly reduce costs for the difficult-to-
treat population. In this RCT, emergency department visits
were significantly reduced in the CBT-ip arm, building on
studies showing that identifying PNES decreases emergency
department use.35
Our study gives the first level 1 data for PNES. Regarding
level of evidence to inform evidence-based treatment36 for
PNES,while numerous open-label anduncontrolled trials are
in the literature, to our knowledge the only 2 pilot RCTs for
PNES include a traditional CBT approach (level 3 data)37 or a
pharmacologic approach (level 2 data).13
Limitationsof thestudywererelatedto its samplesize.This
studywas not an efficacy trial. Despite not being powered for
differences between groups, however, the effect size demon-
stratedsignificantwithin-group reductions in seizuresanddif-
ferences between CBT-ip and TAU on secondary measures.
While no demographic differences were present between
groups, the CBT-ip with sertraline group and the TAU group
showed baseline differences in anxiety, mood, and somatic
symptom scale scores. Despite these differences, all groups
were in the range of moderate to severe symptoms on scales
at baseline. A larger sample size would likely diminish these
differenceswith randomization.Furthermore,nobaselinedif-
ferenceswereobserved for theprimaryoutcomeof seizureand
most of the secondaryvariables, thus indicating that random-
ization occurred for these variables. Despite baseline differ-
ences inanxiety,depression, andsomatic symptoms in2arms,
these few differences did not moderate seizure count for the
4 arms. The trial was not double blind because itwas not pos-
sible with some receiving CBT-ip, some receiving sertraline,
somereceivingCBT-ipwithsertraline,andsomereceivingTAU.
Blinding of the raters to treatment arm, however, provided
blindedassessments. To reflect standardmedical care inTAU,
the study arms differed in that the TAU group received con-
tact with mental health clinicians less frequently than the
CBT-ip and CBT-ip with sertraline arms. Biweekly follow-up
provided a modified exposure control (every 2 weeks in TAU
vs weekly in therapy arms). Biweekly contact with the pa-
tients in the TAU condition was more frequent than the typi-
cal follow-up once every 1 to 3 months but was less frequent
than in other arms. Contact was made, however, at the same
frequency as the sertraline arm. Given the biweekly fol-
low-up in both groups, with the sertraline arm showing some
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improvements and the TAU arm showing no change or wors-
ening, thedifferences arenot attributable to less frequent con-
tact in the TAU arm. The duration of follow-up for this study
was linkedto the treatment.WeobserveddifferenceswithCBT-
ip; however, whether such responses are sustained over time
(ie, whether freedom of PNES is maintained) is being as-
sessed.Thedurability of the responsewill be assessedwith 12-
month follow-upexaminations.Future trials could likewiseas-
sess outcomes of longer duration, eg, 6 or 12 months.
This study was a prelude to a trial planned to include a
larger number of participants and outcome measures differ-
ent from the traditional 50% responder rate (eg, seizure free-
dom). Choosing an appropriate outcomemeasure is germane
to the overall success of such a study.While a 50% responder
rate is theusual outcomemeasure inepilepsy regulatory trials,
such an outcome measure may not be the most optimal one
forPNES.38Thus,whileproviding importantoutcomedata, this
study also addressed several potential difficulties of conduct-
ing such trials in the PNES population, including participant
recruitment and retention (good retention aided by contact
with participants), choice of primary and secondary outcome
measure(s), providing uniform treatments and intervention
across centers, and training individuals on provision of inter-
ventions and collection of outcome data.While the study en-
rolled a relatively small number of participants, considering
the financial limitations and the fact that significant re-
sources were devoted to addressing the difficulties de-
scribed, the study is significant not only for the outcomes but
also because it trained andbuilt a teamof investigators across
several institutions.
There are 3 stages to management of PNES: presentation
of the diagnosis, gaining control of the seizures, andmainte-
nance therapy.27 Research reveals that most patients pre-
sented with the diagnosis of PNES do not have lasting im-
provement in their symptoms.39Maintenance therapies exist
forotherdisorders and, althoughnotyet studied,maybehelp-
ful for PNES. This study assessed the impact of treatments in
the phase of gaining control and treatment. The durability of
the treatmentwill be assessed in future studies. Patientswho
underwent this time-limited interventionnoted that the treat-
ment allowed them to gain control of their once seizure-
dominated life and live a more normal life.
Conclusions
This pilot RCT for PNESdemonstrates that this formofmanu-
alizedpsychotherapy for PNES reduced seizures andother so-
matic symptoms, improved psychiatric symptoms including
depression andanxiety, and improvedQOL, coping skills, and
overall functioning. This study also demonstrates the feasi-
bility of treatment dissemination to other sites.
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